DaVita Non-GAAP EPS of $2.51 misses by $0.66, revenue of $3.42B misses by $10M

* DaVita press release [https://seekingalpha.com/pr/20285170-davita-inc-3rd-quarter-2025-results] (DVA [https://seekingalpha.com/symbol/DVA]): Q3 Non-GAAP EPS of $2.51 misses by $0.66.
* Revenue of $3.42B (+4.9% Y/Y) misses by $10M.

 

Current 2025 guidance

 

Prior 2025 guidance

 

Low

 

High

 

Low

 

High

 

(dollars in millions, except per share data)

Adjusted operating income

$2,035

 

$2,135

 

$2,010

 

$2,160

Adjusted diluted net income per share attributable to DaVita Inc.

$10.35

 

$11.15

 

$10.20

 

$11.30

Free cash flow

$1,000

 

$1,250

 

$1,000

 

$1,250

 

Click to enlarge

* Shares -1.23% AH.

MORE ON DAVITA

* DaVita: Contraction Phase With Incremental Earnings Hurdle (Rating Downgrade) [https://seekingalpha.com/article/4815464-davita-stock-contraction-phase-with-incremental-earnings-hurdle-downgrade-hold]
* DaVita: Aggressive Buybacks Despite Rising Cost Of Debt [https://seekingalpha.com/article/4815208-davita-aggressive-buybacks-despite-rising-cost-of-debt]
* DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4809226-davita-inc-dva-q2-2025-earnings-call-transcript]
* DaVita Q3 2025 Earnings Preview [https://seekingalpha.com/news/4509416-davita-q3-2025-earnings-preview]
* Short bets on S&P 500 Healthcare sector rises marginally to 1.91% in September; MRNA remains most shorted stock [https://seekingalpha.com/news/4503493-short-bets-on-sp-500-healthcare-sector-rises-marginally-to-191-in-september-mrna-remains-most-shorted-stock]